태아연골조직유래 줄기세포원 및 이를 포함하는 세포치료제
    2.
    发明公开
    태아연골조직유래 줄기세포원 및 이를 포함하는 세포치료제 无效
    从胎盘组织和细胞治疗剂衍生的新型干细胞来源

    公开(公告)号:KR1020140016841A

    公开(公告)日:2014-02-10

    申请号:KR1020130090233

    申请日:2013-07-30

    Abstract: The present invention relates to a stem cell source derived from a fetal cartilage tissue and a cellular therapeutic agent comprising the same. The present invention relates to a development of a stem cell source using fetal tissue derived cells, which have less restriction in ethics than the existing known embryonic stem cell, facilitate the control of differentiation, and have more excellent proliferative performance and differentiating performance than adult stem cells. According to the present invention, the cells isolated from the fetal cartilage tissue express a surface antigen specific to embryonic stem cells, such as SSEA-4, and a transcription factor specific to embryonic stem cells, such as Oct4, and also express surface antigens of mesenchymal stem cells, such as Stro-1, CD29, CD90, and CD105. The cells derived from the fetal cartilage tissue are more excellent in the cell proliferative performance and the differentiating performance into various cell tissues than adult stem cells, and thus can be used as a new stem cell source for regenerating damaged tissues. Particularly, the cells derived from the fetal cartilage tissue were verified to form no tumors when being transplanted under the skin of immunosuppressive mice (nude mice), and can be transplanted in the human body at high safety.

    Abstract translation: 本发明涉及源自胎儿软骨组织的干细胞源和包含其的细胞治疗剂。 本发明涉及使用胎儿组织来源的细胞的干细胞来源的发展,其比现有已知的胚胎干细胞具有较少的伦理限制,促进分化的控制,并且具有比成体干细胞更优异的增殖性能和分化性能 细胞。 根据本发明,从胎儿软骨组织分离的细胞表达对胚胎干细胞(例如SSEA-4)特异性的表面抗原,以及对胚胎干细胞(例如Oct4)特异的转录因子,并且还表达表达抗原 间充质干细胞,如Stro-1,CD29,CD90和CD105。 来自胎儿软骨组织的细胞在细胞增殖性能和与各种细胞组织的分化性能方面比成体干细胞更优异,因此可以用作新的干细胞源用于再生受损组织。 特别地,当被移植到免疫抑制小鼠(裸鼠)的皮肤下时,来自胎儿软骨组织的细胞被证实不形成肿瘤,并且可以以高安全性移植到人体内。

Patent Agency Ranking